Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2019 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2019.1467
Abstract: Importance Few studies are available on the role of maintenance strategies after induction treatment regimens based on anti-epidermal growth factor receptors, and the optimal regimen for an anti-epidermal growth factor receptors-based maintenance treatment in patients… read more here.
Keywords: arm; panitumumab plus; maintenance; treatment ... See more keywords
The potential effect of Schisandrin‐B combination with panitumumab in wild‐type and mutant colorectal cancer cell lines: Role of apoptosis and autophagy
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Biochemical and Molecular Toxicology"
DOI: 10.1002/jbt.23324
Abstract: Panitumumab is an approved monoclonal antibody for the treatment of colorectal cancer (CRC); however, mutations in EGFR signaling pathway resulted in poor response. Schisandrin‐B (Sch‐B) is a phytochemical that was suggested to protect against inflammation,… read more here.
Keywords: cell; effect; combination; crc ... See more keywords
Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC
Sign Up to like & getrecommendations! Published in 2019 at "Advances in Therapy"
DOI: 10.1007/s12325-019-0874-6
Abstract: IntroductionThis study aimed to better understand panitumumab use in real-life clinical practice in first- and second-line treatment of metastatic colorectal cancer in five European countries.MethodsThis is a combined analysis of two observational, non-interventional prospective cohort… read more here.
Keywords: clinical practice; first line; line; panitumumab ... See more keywords
A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Immunopharmacology and Immunotoxicology"
DOI: 10.1080/08923973.2022.2112222
Abstract: Abstract Aim Cetuximab and panitumumab are common antibodies against epidermal growth factor receptor (EGFR) that can be used in combination with chemotherapy for the treatment of metastatic colorectal cancer (mCRC). Although these two drugs are… read more here.
Keywords: arm; cetuximab; analysis; panitumumab ... See more keywords
The effectiveness of cetuximab and panitumumab when combined with FOLFIRI in second-line treatment of KRAS wild type metastatic colorectal cancers. Single centre experience
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Chemotherapy"
DOI: 10.1080/1120009x.2020.1861531
Abstract: Panitumumab and cetuximab are monoclonal antibodies known to be effective in metastatic colorectal cancer (mCRC). Although the survival benefits when combined with chemotherapy have been determined, there are no studies comparing the two agents with… read more here.
Keywords: second line; panitumumab; line treatment; cetuximab panitumumab ... See more keywords
Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review
Sign Up to like & getrecommendations! Published in 2017 at "BMC Cancer"
DOI: 10.1186/s12885-017-3740-4
Abstract: BackgroundIn Europe, treatment of metastatic colorectal cancer (mCRC) with panitumumab requires prior confirmation of RAS wild-type mutation status. Two studies – a physician survey and a medical records review (MRR) – were conducted to evaluate… read more here.
Keywords: physician survey; metastatic colorectal; cancer; ras testing ... See more keywords
APOLLON: A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.3523
Abstract: 3523Background: APOLLON is an open-label, single-arm phase I/II study investigating the efficacy and safety of panitumumab (Pmab) in combination with TAS-102 (trifluridine/tipiracil) in pts with RA... read more here.
Keywords: phase study; panitumumab; tas 102; apollon ... See more keywords